D,L-3,4-Dimethyl-2-phenylmorpholin-hydrogentartrat | 50-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: D,L-3,4-Dimethyl-2-phenylmorpholin-hydrogentartrat
• 英文别名: 2,3-Dihydroxybutanedioic acid;3,4-dimethyl-2-phenylmorpholine
• CAS: 50-58-8；4607-47-0；7389-46-0；35721-20-1；63868-62-2
• 化学式: C₄H₆O₆*C₁₂H₁₇NO
• 分子量: 341.361
• InChiKey: VEPOHXYIFQMVHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.04
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  8

安全信息

• 海关编码：
  2934999090

文献信息

• 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
  申请人：de Lera Ruiz Manuel

  公开号：US20070066644A1

  公开（公告）日：2007-03-22

  The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.

  本发明公开了化合物I的结构以及其药学上可接受的盐和溶剂化合物。该发明还涉及包括化合物I的药物组合物，并且其在治疗肥胖症、代谢综合征、糖尿病、肝脂肪病或非酒精性脂肪肝病中的用途。该发明还涉及将化合物I与其他治疗剂的组合物用于治疗肥胖症、代谢综合征、糖尿病、肝脂肪病或非酒精性脂肪肝病。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• sGC STIMULATORS
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：US20180065971A1

  公开（公告）日：2018-03-08

  The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:

  本公开涉及可溶性鸟苷酸环化酶（sGC）的激动剂，包括它们的药物配方及其单独或与一个或多个额外药剂联合使用以治疗各种疾病，其中氮氧化物（NO）浓度增加、环鸟苷酸单磷酸（cGMP）浓度增加、或两者增加，或NO途径上调是可取的。这些化合物属于式I：
• Polymorph Compositions, Methods of Making, and Uses Thereof
  申请人：Macdonald R. Loch

  公开号：US20130302431A1

  公开（公告）日：2013-11-14

  The described invention provides a biodegradable, biocompatible delivery system of flowable sustained release microparticulate composition of a substantially pure crystalline form of a bioactive agent such as, for example, nimodipine, a process of preparing a therapeutic form of a substantially pure crystalline form of the bioactive agent and a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury.

  所述发明提供了一种可生物降解、生物相容的流动持续释放微粒组合物的输送系统，其包含一种基本纯的晶体形式的生物活性剂，例如尼莫地平，以及一种制备基本纯的晶体形式生物活性剂的治疗形式的过程，以及一种治疗哺乳动物脑损伤引起的潜在中断的蛛网膜下腔脑动脉中断的方法，该方法减少与脑损伤相关的至少一种延迟并发症的症状或体征。
• [EN] BICYCLIC MELANOCORIN-SPECIFIC COMPOUNDS<br/>[FR] COMPOSES BICYCLIQUES SPECIFIQUES DE LA MELANOCORTINE
  申请人：PALATIN TECHNOLOGIES INC

  公开号：WO2005079574A1

  公开（公告）日：2005-09-01

  Melanocortin receptor-specific bicyclic compounds having the structure (I) and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, R3 X and z are as described in the specification, which are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor­related disorders and conditions. Pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.

  具有结构（I）和其立体异构体以及药学上可接受的盐的黑色素皮质素受体特异性双环化合物，其中R1、R2、R3、X和z如规范中所述，这些化合物是一种或多种黑色素皮质素受体的激动剂、拮抗剂或混合激动剂和拮抗剂，并且在治疗黑色素皮质素受体相关疾病和症状方面具有用途。还公开了含有结构（I）化合物的药物组合物和与其使用相关的方法。